This study is looking at a new way to treat Wilson's disease (a genetic disorder where too much copper builds up in the body). It compares a new, once-a-day formulation of trientine tetrahydrochloride (TETA 4HCl) with the standard treatment, D-Penicillamine (DPA). The goal is to see if TETA 4HCl is safe and effective as a first treatment for people newly diagnosed with Wilson's disease. You might be able to join if you are 8 years or older, have a recent diagnosis of Wilson's disease, and haven't started copper-removing treatments (chelators) or have only been taking zinc salts for less than 28 days. The main way they'll measure success is by checking the amount of copper in your blood after 48 weeks. The study is currently unclear on its recruitment status.

Study design

This is an interventional study planning to enroll 38 participants. You would be randomly assigned (like a coin toss) to receive either TETA 4HCl or DPA.

What's involved

You would receive either TETA 4HCl once a day or DPA according to standard practice for 48 weeks. There will be a 28-day screening period before treatment begins.

Compensation

Not stated in the trial record.

Follow-up

You will be followed for 48 weeks after being randomly assigned to a treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.